Merus (NASDAQ:MRUS) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research cut shares of Merus (NASDAQ:MRUS) from a buy rating to a hold rating in a research report report published on Saturday morning, Zacks.com reports.

According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “

Other equities analysts have also issued reports about the stock. Guggenheim initiated coverage on shares of Merus in a research report on Friday, April 12th. They issued a buy rating and a $25.00 price objective for the company. Roth Capital initiated coverage on shares of Merus in a research report on Friday, June 28th. They issued a buy rating and a $20.00 price objective for the company. Finally, BidaskClub upgraded shares of Merus from a sell rating to a hold rating in a research report on Saturday, July 13th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Merus presently has an average rating of Buy and a consensus target price of $22.57.

NASDAQ:MRUS traded up $0.52 on Friday, reaching $16.12. 40,346 shares of the company’s stock were exchanged, compared to its average volume of 45,523. The firm has a market capitalization of $354.91 million, a price-to-earnings ratio of -8.76 and a beta of 0.22. Merus has a 52 week low of $11.00 and a 52 week high of $22.46. The company has a fifty day moving average of $15.06.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, May 30th. The biotechnology company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.22. Merus had a negative net margin of 75.71% and a negative return on equity of 39.46%. The company had revenue of $8.75 million during the quarter, compared to analyst estimates of $7.47 million. On average, research analysts forecast that Merus will post -1.9 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC lifted its position in Merus by 10.3% during the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,100 shares during the last quarter. Geode Capital Management LLC lifted its position in Merus by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 2,373 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 3,389 shares during the last quarter. Artal Group S.A. lifted its position in Merus by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock valued at $5,128,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Granite Investment Partners LLC bought a new stake in Merus during the first quarter valued at approximately $468,000. Institutional investors own 52.13% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Read More: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.